MENS — Jyong Biotech Ltd. Ordinary Shares Stock Price, Chart & AI Report

Positive Oct 7, 2025 • 20:09 UTC Benzinga • Piero Cingari

Trump Sparks A 2025 IPO Boom: 5 New Stocks Have Rallied Over 400%

The U.S. IPO market is experiencing a strong revival in 2025, with 163 companies going public and raising $31 billion, driven by a favorable business climate under President Trump's second term and increased investor risk appetite.

EPSM MENS ANPA DGNX IPO stock market Trump investment

Sentiment note

Significant stock price surge of 647.27% since June IPO, reaching over $4 billion market cap

Neutral Sep 3, 2025 • 11:30 UTC The Motley Fool • James Brumley

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.

EQ CGTX IPDN MENS Nasdaq biopharma stock performance drug development

Sentiment note

188% increase primarily due to investor discovery after IPO, with promising phase 3 drug testing

Positive Aug 22, 2025 • 13:00 UTC GlobeNewswire Inc. • Jyong Biotech Ltd.

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

Jyong Biotech presented Phase III clinical trial results for BOTRESO, a drug for benign prostatic hyperplasia, and Phase II results for MCS-8, a potential prostate cancer prevention drug, at the 22nd Urological Association of Asia Congress.

MENS biotechnology clinical trials urology prostate health drug development

Sentiment note

Demonstrated promising clinical trial results for two drug candidates, showed statistically significant improvements in lower urinary tract symptoms, and received positive feedback on long-term safety and efficacy